Debuting author Chris Iachetta bares all in ‘The Book of Laz’

New memoir recounts the journey of a young man who beats the odds in front of him and finds happiness and success in the end

LOS ANGELES, Dec. 04, 2020 (GLOBE NEWSWIRE) — Chris Iachetta ventures into the world of publishing to share his inspiring story of hope and survival amid life’s challenges in his memoir, “The Book of Laz” (published by Archway Publishing).

 

Born Lazarus, this debuting author had to contend with everything — from abuse to assault and attempted murder growing up. Whether it was his birth mother, his foster families or adoptive parents, no one seemed to care or want him. Even the police were not on his side. At age 16, he was arrested for defending himself against abuse. He spent birthdays and holidays alone in a group home, thinking of ways to end his life. Everyone told him he would end up in jail or dead. But, at the group home, he met people who changed his life. They put him in check, gave him love and helped him realize that life was worth living. While the odds were stacked against him, he beat them.

 

Raw and honest in its telling, “The Book of Laz” tells the miraculous story of how a young man kept fighting and never let his past dictate his future. It gives the reader an inside look at what it is like to be abused and overlooked, go through the foster care system, get locked up, and somehow beat all the odds to become successful.

 

“Everyone struggles in some way or another and I just want to share my story in hopes that it will help someone else overcome what they’re going through,” Iachetta states. “I want them to feel like they’re not alone. That we all go through things, and no matter how dark they may seem, there’s always a way to overcome. I also want people to be able to find humor in every situation, even the dark ones.”

 

Visit  https://www.archwaypublishing.com/en/bookstore/bookdetails/816698-the-book-of-laz to get a copy of the book.

 

“The Book of Laz”

By Chris Iachetta

Hardcover | 5.5 x 8.5in | 132 pages | ISBN 9781480898325

Softcover | 5.5 x 8.5in | 132 pages | ISBN 9781480898349

E-Book | 132 pages | ISBN 9781480898332

Available at Amazon and Barnes & Noble

 

About the Author

Chris Iachetta grew up in upstate New York. He lives in Los Angeles with his wife, Mallory, and their cat, Nala. “The Book of Laz” is his first book.

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit www.archwaypublishing.com or call 844-669-3957.

Attachment



Marketing Services
Archway Publishing
844-669-3957
[email protected]

Skanska invests in land in Massachusetts, USA, for USD 177M, about SEK 1.5 billion

PR Newswire

ÖSTERSUND, Sweden, Dec. 4, 2020 /PRNewswire/ — Skanska has acquired about 2,787 square meters of land in Boston, Massachusetts. The seller is John Hancock Life Insurance Company. The land acquisition amounts to USD 177M, about SEK 1.5 billion.

Located at 380 Stuart Street in the Back Bay neighborhood of Boston, Skanska plans to develop a 27-story, about 58,000 square meter, Class-A office building with ground-floor retail and below-ground parking. The project will target LEED® Platinum, Fitwell, and WiredScore certifications.

The development site is in the center of the city’s commuter hub, with close proximity to the Boston Public Garden, Boston Common, and the trendy shopping district of Newbury Street. This acquisition marks Skanska’s seventh commercial venture in Greater Boston, and one of the few remaining opportunities for a new, ground-up development in Back Bay.

Since 2009, Skanska USA Commercial Development has invested more than USD 2 billion in office and multi-family projects, and has developed office headquarters for tenants including, Waste Management, Bank of America, Brooks Sports, PricewaterhouseCoopers and Tommy Bahama.

Skanska is one of the leading construction and development companies in USA, specializing in building construction, civil infrastructure and developing commercial properties in select U.S. markets. Skanska USA had sales of SEK 74 billion and about 7,900 employees in its operations in 2019.

For further information please contact:

Alicia Jones

Director – Communications
Skanska USA
tel + 1 703 835 2762

Olof Rundgren

Media Relations Manager
Skanska AB
tel + 46 (0)10 448 67 94

Direct line for media, tel +46 (0)10 448 88 99

This and previous releases can also be found at

www.skanska.com
.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skanska/r/skanska-invests-in-land-in-massachusetts–usa–for-usd-177m–about-sek-1-5-billion,c3248992

The following files are available for download:


https://mb.cision.com/Main/95/3248992/1344065.pdf

20201204 US land Massachusetts

 

Cision View original content:http://www.prnewswire.com/news-releases/skanska-invests-in-land-in-massachusetts-usa-for-usd-177m-about-sek-1-5-billion-301186400.html

SOURCE Cision AB

Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab

PR Newswire

LUND, Sweden, Dec. 4, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an approved IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND approval by the US Food and Drug Administration (FDA) is a prerequisite to start clinical trials in the USA. Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab.

“While the upcoming clinical Phase Ib/II study in pancreatic cancer, OPTIMIZE-1, will be starting in Europe, the IND opens up for later expansion in the US. This is essential for the future success of the product”, said Per Norlén, CEO of Alligator Bioscience.”, said Per Norlén, CEO of Alligator Bioscience. “Our key focus right now is to complete the submission of the CTA for start of OPTIMIZE-1 in the EU”, he added.

The mitazalimab drug candidate has previously reported positive clinical data from a Phase I study performed by Janssen Biotech Inc., displaying a manageable safety profile as well as early signs of efficacy.

For further information, please contact:

Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: [email protected] 

The information was submitted for publication, through the agency of the contact person set out above, at 9:00 a.m. CET on December 4, 2020.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc.). In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/alligator-bioscience/r/approved-ind-for-alligator-bioscience-s-cd40-targeting-antibody-mitazalimab,c3249146

The following files are available for download:


https://mb.cision.com/Main/12681/3249146/1344206.pdf

Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab

 

Cision View original content:http://www.prnewswire.com/news-releases/approved-ind-for-alligator-biosciences-cd40-targeting-antibody-mitazalimab-301186398.html

SOURCE Alligator Bioscience

Investor Alert: Ademi LLP Investigates Possible Securities Fraud of Splunk Inc.

PR Newswire

MILWAUKEE, Dec. 4, 2020 /PRNewswire/ — Ademi LLP is investigating possible securities fraud claims against Splunk (NASDAQ: SPLK) resulting from inaccurate statements Splunk made regarding its financial statements and prospects.

Click here to learn more about the investigation: http://ademilaw.com/case/splunk-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

The investigation focuses on whether Splunk issued false and misleading statements regarding its financial statements and prospects during 2020.  Specifically, Splunk’s third quarter results and management’s guidance for fourth quarter were below analysts’ expectations. Revenue for the third quarter was $559 million, down 11% compared to last year. Analysts were expecting revenue of approximately $613 million. Splunk also reported an adjusted loss per share of $1.26, shockingly lower than the $0.09 per share in profit analysts had been predicting.  BTIG stated that Splunk’s explanation for these dismal financial results was “confusing given that most peers in the software space (and particularly in security software) saw relatively strong trends” in the quarter. Most analysts downgraded Splunk, with JPMorgan stating that it was “blindsided by the magnitude of too many large deals slipping in the final days of October.”

If you wish to obtain additional information or have information about this investigation of Splunk, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, http://ademilaw.com/case/splunk-inc.                     

We specialize in securities fraud and shareholder litigation.  For more information, please feel free to call us.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com

 

Cision View original content:http://www.prnewswire.com/news-releases/investor-alert-ademi-llp-investigates-possible-securities-fraud-of-splunk-inc-301186345.html

SOURCE Ademi LLP

Accused of treason and being a double agent, Michael Vaux must clear his name in new espionage thriller

‘The Algerian Hoax’ is the fifth book in Roger Croft’s ‘Mideast Spy’ series

TORONTO, Dec. 04, 2020 (GLOBE NEWSWIRE) — Skilled British spy Michael Vaux is under suspicion for treason due to anonymous tips and now must prove his innocence before the real culprit gets away in Roger Croft’s new action and adventure novel titled “The Algerian Hoax: A New Michael Vaux Novel” (published by Archway Publishing).

 

Michael Vaux, former journalist and occasional secret agent for Britain’s MI6 must overcome betrayal and double-dealing within the spy networks of major Mideast players such as the UK, Israel and the major Arab nations in this espionage thriller. Suspected of being a long-term double agent for a Mideast nation, Michael needs to uncover the real mole in order to clear his name and save his life

 

“No spy novelist has created or imagined a character like Michael Vaux. No spy novelist has ever written about Department B3,” Croft states. “This is Vaux’s fifth assignment and readers who have followed the Vaux series will want to know whether MI6’s suspicions about Vaux’s loyalty to queen and country are justified.”

 

“The Algerian Hoax” is available for purchase online at: https://www.amazon.com/Algerian-Hoax-Michael-Vaux-Novel/dp/1480891908.  

 

“The Algerian Hoax”

By Roger Croft

Hardcover | 5.5 x 8.5 in | 206 pages | ISBN 9781480891906

Softcover | 5.5 x 8.5 in | 206 pages | ISBN 9781480891890

E-Book | 206 pages | ISBN 9781480891883

Available at Amazon and Barnes & Noble

 

About the Author

Roger Croft is a former journalist whose reports and feature articles have appeared in numerous publications including The Economist, Sunday Telegraph and Toronto Star. He has also worked in Egypt where he freelanced and wrote editorials for The Egyptian Gazette. He has also written “The Wayward Spy,” “Operation Saladin,” “The Maghreb Conspiracy,” “Warehouse of Souls,” “Bent Triangle” and “Swindle!”

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit www.archwaypublishing.com or call 844-669-3957.

Attachment



Marketing Services
Archway Publishing
844-669-3957
[email protected]

Polygiene and Eye-care innovator Body Doctor now increase the range of soothing eye compresses and face masks

PR Newswire

STOCKHOLM, Dec. 4, 2020 /PRNewswire/ — Body Doctor specializes in eye-care, eyelid hygiene products and have transformed the market for eye compresses and continue establishing a pedigree of bringing innovation to the sector with an antibacterial fabric thanks to the partnership with Polygiene®. In addition, Body Doctor will offer their AB+ face masks with Polygiene ViralOff® antimicrobial technology with launch date in December.  

Polygiene Biostatic technology is incorporated in all the Eye Doctor Sterileyes® eye compresses, a unique feature that has become a core component of the company’s overall product offering and performance. With an exclusivity agreement and very strong sales momentum in 2020 – order value of approximately 1 million sek, Polygiene expects to see even higher numbers in 2021. 

“We selected Polygiene for the extensive expertise that was apparent from data supplied and the individuals we worked with. We had full confidence in Polygiene, and they worked with us to ensure that the antibacterial solution supplied would pass the additional rigorous testing we needed to undertake. We needed to ensure that there would be no detrimental effects to individuals applying our coated compresses to their eyes whilst still offering the reassurance of an effective antibacterial on the product. This was a 3 months long test which we passed successfully”, says Sue Grant, founder of Body Doctor. 

“It is great to see that Polygiene can add value in new sectors like this, where testing and demands are rigorous – a good example is the Medical Class I approval that the antibacterial compresses have received. We see a long-term partnership with Body Doctor and want to continue being an important part in their successful developments of unique products, like the eye compresses”, says Ulrika Björk, CEO Polygiene. 

About Body Doctor

The Body Doctor Ltd was founded in 2012 by Sue Grant and her two sons, Adam & Sam Wymer. Sterileyes®/Polygiene overcomes the difficult challenge of creating an antibacterial fabric that is strong enough to kill bacteria, while also being completely safe to use on and around the eyes. It creates a significant differentiation to all other eye compresses that do not have an anti-bacterial quality. The Eye Doctor is designed to treat some of the most common eye diseases and complaints, like Dry Eye Disease. The AB Mask was created in July 2019. A member of staff that suffers with Cystic Fibrosis asked the company to make a face mask using our antibacterial fabric. As a result, his CF Consultant requested a supply for his patients, we subsequently donated these to the hospital and also the Cystic Fibrosis Care Charity. 2020 of course has seen the Coronavirus pandemic, we have increased production on the AB Mask and now sell the product into general markets as well. 

Press contact Body Doctor: [email protected]

Press contact Polygiene: 
Ulrika Björk
[email protected]
+46 70 921 12 75

For press images, visit 
https://news.cision.com/se/?n=polygiene-ab.

Subscribe here to get reports, press releases and News 
http://ir.polygiene.com/en/press/subscribe/

About Polygiene

As the world leader in stays fresh and odor control technologies, we want to change the way we view clothes – from fast consumables to durables. We treat clothes, home products and textiles to help people stay fresh, wash less and let clothes and products live longer. Over 140 global premium-brands have chosen to use the Polygiene brand with their products. Polygiene is listed on Nasdaq First North Growth Market in Stockholm, Sweden. For more information: www.polygiene.com. Erik Penser Bank AB acts as its Certified Adviser. Phone: +46 8- 463 83 00, e-mail: [email protected].

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/polygiene-ab/r/polygiene-and-eye-care-innovator-body-doctor-now-increase-the-range-of-soothing-eye-compresses-and-f,c3249045

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/polygiene-and-eye-care-innovator-body-doctor-now-increase-the-range-of-soothing-eye-compresses-and-face-masks-301186395.html

SOURCE Polygiene AB

Learn how to handle your CrankaTsuris to make the world a happier and healthier place with new book

Steven Joseph announces publication of ‘A Grownup Guide to Effective Crankiness’

HOBOKON, N.J., Dec. 04, 2020 (GLOBE NEWSWIRE) — Steven Joseph’s ultimate guide to using crankiness titled “A Grownup Guide to Effective Crankiness: The CrankaTsuris Method” (published by Archway Publishing) explores how to be cranky while still having fun and making everyone happy.

 

The self-help book closely examines all the different situations that can cause crankiness or a “CrankaTsuris,” and gives the reader guidance on how to better handle their CrankaTsuris to make the world a happier and healthier place. “A Grownup Guide to Effective Crankiness” features many different stories that include a talking caterpillar, a talking dog and a talking fly. Cain and Able and many others make a special appearance. Given the seriousness of the Common CrankaTsuris, this book assists the reader in both the diagnosis and treatment of the Common CrankaTsuris.

 

“I want my readers to feel that they have permission to embrace their own crankiness, but discard the shackles of any pain that their crankiness may cause,” Joseph says.

 

“A Grownup Guide to Effective Crankiness” is available from Amazon at: https://www.amazon.com/Grownup-Guide-Effective-Crankiness-Crankatsuris/dp/1480893811

 

“A Grownup Guide to Effective Crankiness”

By Steven Joseph

Hardcover | 6 x 9 in | 206 pages | ISBN 9781480893818

Softcover | 6 x 9 in | 206 pages | ISBN 9781480893818

E-Book | 206 pages | ISBN 9781480893825

Available at Amazon and Barnes & Noble

 

About the Author

Steven Joseph is an attorney, son of a Holocaust survivor, marathon runner, and author of the children’s book “The Last Surviving Dinosaur: The TyrantoCrankaTsuris.” He resides in Hoboken, New Jersey. More information is available at www.StevenJosephAuthor.com.

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit www.archwaypublishing.com or call 844-669-3957.

Attachment



Marketing Services
Archway Publishing
844-669-3957
[email protected]

Pomerantz Law Firm Announces the Filing of a Class Action against Turquoise Hill Resources Ltd., Rio Tinto plc, Rio Tinto Limited, Rio Tinto International Holdings Limited, and Certain Officers – TRQ

PR Newswire

NEW YORK, Dec. 4, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Turquoise Hill Resources Ltd.  (“Turquoise Hill” or the “Company”) (NYSE: TRQ), Rio Tinto plc, Rio Tinto Limited (together with Rio Tinto plc, “Rio Tinto”), Rio Tinto subsidiary Rio Tinto International Holdings Limited, and certain of their officers.  The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-10198, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Turquoise Hill securities from July 17, 2018 to July 31, 2019, inclusive (the “Class Period”), and who were damaged thereby, subject to certain exclusions.  Plaintiff seeks to recover compensable damages on behalf of Plaintiff and the Class caused by Defendants’ violations of the federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Turquoise Hill securities during the Class Period, you have until December 14, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action] 

Turquoise Hill is an international mining company focused on the operation and development of the Oyu Tolgoi copper-gold mine in Southern Mongolia (“Oyu Tolgoi”), which is the Company’s principal and only material resource property.  Turquoise Hill’s subsidiary, Oyu Tolgoi LLC, holds a 66% interest in Oyu Tolgoi, and the remainder is held by the Government of Mongolia.

Rio Tinto plc and Rio Tinto Limited are operated and managed together as a single economic unit and engage in mining and metals operations in approximately thirty-five countries.  Through their subsidiaries, Rio Tinto owns 50.8% of Turquoise Hill.  A Rio Tinto subsidiary, Rio Tinto International Holdings, Inc. (“Rio Tinto International” or “RTIH”; and collectively with Rio Tinto plc and Rio Tinto Limited, “Rio Tinto”), is also the manager of the Oyu Tolgoi project, including having responsibility for its development and construction.

The complaint alleges that thought the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the progress of underground development of Oyu Tolgoi was not proceeding as planned; (ii) there were significant undisclosed underground stability issues that called into question the design of the mine, the projected cost, and timing of production; (iii) the Company’s publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (iv) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what the Company had represented; and (v) Turquoise Hill would require additional financing and/or equity to complete the project.

On February 26, 2019, after the close of trading, Turquoise Hill shocked the financial markets by disclosing in a press release that, although “the [Oyu Tolgoi] project cost was expected to remain within the $5.3 billion budget,” a review had determined that “there was an increasingly likely risk of a further delay to sustainable first production beyond Q3’21.”  In the press release, the Company attributed the “likely risk” to productivity delays in completing Shaft 2 and “challenging ground conditions that have had a direct impact on the project’s critical path.”

In response to this news, Turquoise Hill’s common share price closed at $1.83 per share on February 27, 2019, a 12.86% decline from the close at $2.10 per share on February 26, 2019, on a trading volume of over 18 million shares—more than four times greater than the average daily trading volume over the prior year.

Four and a half months later, on July 15, 2019, after the close of trading, Turquoise Hill issued a press release announcing a further delay and that the underground project would cost substantially more than the Company had repeatedly stated during the Class Period.  Sustainable first production from the underground development of Oyu Tolgoi would now be delayed by a further nine to twenty-one months until May 2022 to June 2023, and “the development capital spend for the project may increase by $1.2 to $1.9 billion over the $5.3 billion previously disclosed.”  Turquoise Hill attributed the change to “[i]mproved rock mass information and geotechnical data modeling,” which “confirmed that there are stability risks associated with components of the existing mine design.”  Turquoise Hill disclosed that the issues with the mine design were so unsettled that it would take until the second half of 2020 to develop a revised design for the mine.

Following this news, Turquoise Hill’s common share price closed at $0.60 per share, down 43.93% from the prior day’s closing price of $1.07 per share, with over 50.2 million shares traded.

On July 31, 2019, after the close of trading, Turquoise Hill issued a press release and Management Discussion & Analysis (“MD&A”) making further disclosures about the status of the project, including that Turquoise Hill took a $600 million impairment charge and a substantial “deferred income tax recognition adjustment” tied to the Oyu Tolgoi project, and that it suffered a loss in the second quarter.  The next day, before trading hours, Rio Tinto issued a release concerning in part the project status, including that it had also taken an impairment charge related to the Oyu Tolgoi project, of $800 million.

Following this news, on August 1, 2019, Turquoise Hill’s common share price closed at $0.53 per share, down 8.62% from the prior day’s closing price of $0.58 per share, with over 16.6 million shares traded.

After the Class Period, on July 2, 2020, Turquoise Hill and Rio Tinto announced that the revised feasibility study for the Oyu Tolgoi project had been completed.  The study recommended a new design for the portion of the mine undergoing development, with the addition of structural pillars and other changes, resulting in a reduction to the estimated mineral reserves for the mine.  Turquoise Hill’s press release also warned that the Oyu Tolgoi team was engaged in “re-design studies” for other portions of the underground mine.  Turquoise Hill estimated that there would be an increase in capital costs of $1.5 billion (with a range of $1.3 billion to $1.8 billion), “subject to further studies and any additional scheduling delays or increases in capital costs arising from the impacts of the COVID-19 pandemic.”

Also, on September 10, 2020, Turquoise Hill and Rio Tinto announced that they had entered into a non-binding Memorandum of Understanding under which they would seek to “reprofile Oyu Tolgoi’s existing debt” and raise an additional $500 million through debt financing, plus up to $3.6 billion in equity—thereby diluting Turquoise Hill’s public shareholders.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-turquoise-hill-resources-ltd-rio-tinto-plc-rio-tinto-limited-rio-tinto-international-holdings-limited-and-certain-officers–trq-301186352.html

SOURCE Pomerantz LLP

EchoStar Mobile Partners with Jersey Telecom to Bring Ubiquitous, Hybrid Network Capability to Europe

PR Newswire

DUBLIN, Dec. 4, 2020 /PRNewswire/ — EchoStar Mobile today announced a partnership with Jersey Telecom (JT) to bring true, hybrid satellite/cellular capability to Internet of Things (IoT) and Mobility customers across Europe and the UK.

EchoStar Mobile is combining its European S-band mobile satellite network with the JT 4G platform to offer a cellular roaming network for its new SYNERGY service suite. EchoStar Mobile SYNERGY’s industry-first hybrid approach brings to market a single terminal, single subscription, and a single management interface for a networking solution that uses both mobile satellite and cellular connectivity. It offers comprehensive, cost-effective hybrid connectivity to users across Europe and the UK, ensuring that applications, people, and things have the best possible connectivity, whether at fixed locations or on the move, from dense urban areas to the most remote regions.

“As sectors, companies and application developers continue to plan and execute their digitalisation strategies, the need for simple, highly reliable connectivity has never been more important,” said Telemaco Melia, senior director commercial operations, EchoStar Mobile. “This partnership with JT allows us to enable the technology strategies of our customers wherever they are, without the need for complex technical deployments or the hefty price tag often associated with mobile satellite services and hybrid communication solutions.”

“The demand for ubiquitous pan-European data that spans borders and networks is unprecedented and continues to grow, as enterprises look to optimise their IoT deployments,” said Barna Kutvolgyi, Managing Director, JT International. “This partnership combines the comprehensive capabilities of JT’s platform with EchoStar Mobile’s leading technologies, to reduce complexity and deliver comprehensive coverage in a streamlined solution for EchoStar Mobile’s customers across Europe.”

About EchoStar Mobile
EchoStar Mobile, an Irish company with commercial operations headquartered in the United Kingdom and a data centre based in Griesheim, Germany, is a mobile operator that provides connectivity across Europe through a converged satellite and terrestrial network. For more information, visit EchoStarMobile.com.

About EchoStar
EchoStar Corporation (NASDAQ: SATS) is a premier global provider of satellite communication solutions. Headquartered in Englewood, Colo., and conducting business around the globe, EchoStar is a pioneer in secure communications technologies through its Hughes Network Systems and EchoStar Satellite Services business segments. For more information, visit www.EchoStar.com. Follow @EchoStar on Twitter.

About Jersey Telecom
From its origins in Jersey in 1888, JT is an innovative global telecommunications firm, employing more than 600 people in 7 global locations, and powering close to 10 million SIMS worldwide.

Our clear purpose is to connect our customers to their sustainable future. To do that, we form long-standing partnerships with leading communications businesses to deliver the products and services expected from a full-service, world-class communications provider.

For example, our Internet of Things business provides cellular connectivity and remote management of devices worldwide, as well as fraud protection and bulk messaging services.

Owned by the people of Jersey, JT has completed a socially inclusive project to install a full-fibre broadband network in Jersey, making the island the first jurisdiction in the world to have 100% full-fibre connectivity to all premises, with the third fastest broadband speeds in the world. From January 2020, JT’s minimum guaranteed broadband speeds doubled from 250 Mbit/s to 500 Mbit/s with plans to increase this to 1 Gbit/s.

Our customers also enjoy an award-winning 4G mobile network, with 5G trials currently underway.

www.jtglobal.com     
https://twitter.com/jtsocial
https://www.linkedin.com/company/jt-group-limited/ 
 JT Group Limited

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/echostar-mobile-partners-with-jersey-telecom-to-bring-ubiquitous-hybrid-network-capability-to-europe-301186306.html

SOURCE EchoStar Mobile

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

  • Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.
  • Clover’s vaccine candidates both demonstrated a favorable safety and tolerability profile, and have also shown long-term stability at 2-8oC, making them suitable for global distribution.
  • A global phase 2/3 trial evaluating the safety and efficacy of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020 funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
  • A separate pivotal Phase 2/3 clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum is intended to start in the first half of 2021 to maximize the potential supply of more than 1 billion doses of Clover’s COVID-19 vaccines to the world.

CHENGDU, China.–(BUSINESS WIRE)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced positive clinical data from its Phase 1 trial demonstrating that its protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) induces strong immune responses, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in 150 adult and elderly participants. The manuscript describing the detailed results will be accessible on an online preprint server shortly.

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. S-Trimer adjuvanted with GSK’s pandemic adjuvant system induced neutralizing antibody titers (seroconversion) in 100% of participants at the selected 9 µg S-Trimer dose in both adult and elderly groups, with geometric mean titers (GMT) greater than 1:1,800. CpG-1018/alum-adjuvanted S-Trimer induced neutralizing antibodies in 100% of adult participants at the selected 30 µg S-Trimer dose with GMT greater than 1:1,000, and seroconversion was observed in 88% (7 out of 8) in elderly. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.

Preliminary results from stability studies have demonstrated that S-Trimer is stable at 2-8o C for at least six months (longer-term stability studies are ongoing) and stable at room temperature and 40o C for at least one month, in line with the adjuvants tested. Thus, the ability of Clover’s COVID-19 vaccine candidates to be stored in standard refrigeration temperatures makes them suitable for broad global distribution based on current results.

Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021.

Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, said, “With positive results from our Phase 1 clinical trial demonstrating strong neutralizing immune responses and favorable safety profiles, we look forward to moving our COVID-19 vaccines into the final stages of clinical development. Combined with our ability to potentially produce more than one billion doses of antigen annually and the stability of our vaccines under standard refrigeration conditions, our adjuvanted COVID-19 S-Trimer vaccines are positioned to be well-suited for worldwide distribution. We and our collaborators are steadfast in our commitment to the development of safe, effective and accessible COVID-19 vaccines for the global population.”

Thomas Breuer, Chief Medical Officer of GSK Vaccines, commented, “We are delighted by the promising Phase 1 clinical data underscoring the robust and rapid immune response elicited by GSK’s pandemic adjuvant system combined with Clover’s antigen – in both, adults and older adults and are looking forward to demonstrate the public health value in the upcoming efficacy trial. These results – in addition to results from the combination of our adjuvant with other COVID-19 vaccine technologies – show GSK’s commitment to provide scalable solutions to tackle the pandemic around the globe.”

Rob Janssen, Chief Medical Officer of Dynavax, commented, “We are pleased with the strong immune responses and an outstanding safety profile of Clover’s S-Trimer vaccine adjuvanted with Dynavax’s advanced CpG 1018 adjuvant plus alum. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection. We are proud to be partnered with Clover in our endeavors to develop a safe and effective COVID-19 vaccine that will be readily accessible around the world to combat this ongoing pandemic.”

The Phase 1 clinical trial was funded by the Coalition for Epidemic Preparedness Innovations (CEPI). “This is very promising Phase 1 data which warrants further clinical development of Clover’s S-Trimer vaccine candidate, “ Dr. Richard Hatchett, Chief Executive Officer of CEPI commented, “This vaccine candidate has the potential to be manufactured at scale and stored in a regular refrigerator which makes it suitable for use around the globe, including in low-resource settings. Through our partnership with Clover we hope to make hundreds of millions of doses of this vaccine globally accessible through COVAX, if it is proven to be safe and effective.”

About COVID-19 S-Trimer Vaccine

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development. S-Trimer resembles the native trimeric viral spike protein and is produced via a rapid mammalian cell-culture based expression system. S-Trimer is intended to be adjuvanted.

About Trimer-Tag© Technology

Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. Many major disease targets are trimerization-dependent such as the tumor necrosis factor (TNF) superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells. Clover is using its Trimer-Tag© technology with global IP position to develop recombinant trimerized fusion proteins that are able to effectively target these previously undruggable pathways.

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. Having raised more than USD $350 million in total capital since 2016, Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house GMP biomanufacturing capabilities to support large-scale production of its biologic therapies. For more information, please visit our website:  www.cloverbiopharma.com.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally. For further information please visit https://www.gsk.com/en-gb/about-us/

About Dynavax

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships. For more information, visit www.dynavax.com

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated nine partnerships to develop vaccines against the novel coronavirus. The programs will leverage rapid response platforms already supported by CEPI as well as new partnerships.

Before the emergence of COVID-19 CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).

Clover Biopharmaceuticals:

Cindy Min

Vice President, Public Affairs

[email protected]

+86 010-82022601

Media Contact:

Alison Chen

LifeSci Communications

[email protected]

+1 646-876-4932

KEYWORDS: China Asia Pacific

INDUSTRY KEYWORDS: FDA Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo